Products and Services
-
Rocket Science Health announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 12,569,658, titled “Dual Nozzles For Insertion Into Paired Body Orifices (e.g., Nasal Passages, Etc.)” covering the company’s intranasal… Read more . . .
-
Device company Nemera and UK-based pharma company Therakind have announced a deal that will allow Nemera to add Therakind’s DriDose intranasal dry powder delivery technology to its portfolio. Therakind, which is developing several nasal DPI products… Read more . . .
-
CDMO Experic and particle engineering specialist Flurry Powders have announced a partnership to offer development services for inhaled and nasal drug formulations that require specialized particle engineering and manufacturing. The companies cite potential opportunities for dry… Read more . . .
-
Zydus Lifesciences has announced the launch of a foldable MDI spacer after acquiring marketing and commercialization rights to the device from Mumbai-based AeroDel Technology Innovations. The spacer, which AeroDel calls A202, is being marketed by… Read more . . .
-
Australian biopharm Covirix Medical, which is developing a broad-spectrum antiviral, has signed a letter of intent with Aptar Pharma for a feasibility study evaluating delivery of the antiviral via Aptar’s Orbital dry powder inhaler. The… Read more . . .
-
Orbia Fluor & Energy Materials (previously Koura, Mexichem) has announced the submission of a drug master file for its HFA 152a MDI propellant, marketed as Zephex 152a. The company kicked off the transition to low global warming potential… Read more . . .
-
Chiesi and Inhalation CDMO Bespak have announced an expansion of an existing partnership to increase manufacturing capacity for LGWP propellant MDIs at Bespak’s Holmes Chapel, UK site. Chiesi announced plans to launch an HFA 152a inhaler by… Read more . . .
-
US-based CDMO Kenox Pharmaceuticals announced that it is now able to offer clinical manufacturing for OINDPs and has expanded its testing services for OINDPs, including in vitro BE. In January 2025, the company said that it… Read more . . .
-
Iconovo announced that it has signed a letter of intent with CDMO Lonza related to development of spray dried formulation of inhaled biologics. The companies announced in January 2025 that Lonza would develop spray dried… Read more . . .
-
Israeli psychedelic drug developer Clearmind Medicine has signed an agreement with Polyrizon for development of an intranasal formulation of Clearmind’s 5‑methoxy‑2‑aminoindane (MEAI) based on Polyrizon’s intranasal hydrogel technology, the companies said. According to Clearmind, MEAI… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA